Abbott Announces First-of-Its-Kind Trial to Assess New Therapy Option for People at Risk of Stroke
Abbott Laboratories (ABT)
Last abbott laboratories earnings: 4/16 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
abbott.com/investors.html
Company Research
Source: PR Newswire
ABBOTT PARK, Ill., Feb. 3, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved a new trial designed to assess its Amplatzer™ Amulet™ Left Atrial Appendage Occluder for people with atrial fibrillation (AF) – a condition in which the normal rhythm of the heart's upper chambers is disrupted and becomes erratic – who are at risk of stroke. The CATALYST trial is the first-ever clinical trial comparing the effectiveness of a left atrial appendage (LAA) closure device to a newer class of blood thinners, known as non-vitamin K antagonist oral anticoagulant (NOAC) drugs, which are currently the standard treatment option for AF. Atrial Fibrillation is the most common sustained cardiac arrhythmia, with the prevalence in the U.S. projected to increase to 12.1 million by 2030.i In some people with AF, the LAA – a small, naturally occurring pocket connected to the upper left chamber of the heart – can allow blood to pool, leading to
Show less
Read more
Impact Snapshot
Event Time:
ABT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABT alerts
High impacting Abbott Laboratories news events
Weekly update
A roundup of the hottest topics
ABT
News
- Global Bionic Devices Industry Research, 2023-2024 & 2030: Addressing Diverse Healthcare Needs Worldwide to Sustain Growth and Fuel Develoments [Yahoo! Finance]Yahoo! Finance
- Valcare Medical, Inc. Announces Corporate Restructuring and Appointment of New CEO [Yahoo! Finance]Yahoo! Finance
- Europe In-Vitro Diagnostics (IVD) Markets, 2023-2024 & 2029 with Abbott, bioMerieux, Danaher, Hoffmann-La Roche, Bio-Rad, Siemens Healthineers, Thermo Fisher Scientific, and Diasorin Dominating [Yahoo! Finance]Yahoo! Finance
- Autoimmune Collaboration and Licensing Deals Report 2024: Provides Details of 882 Autoimmune Deals Dating Back to 2016 by Company, Headline Value, Therapeutic Area and Technology Type [Yahoo! Finance]Yahoo! Finance
- Drug Discovery Global Market Report and Growth Forecasts 2023-2030: Collaborative Research Models, Personalized Medicine and Repurposing Existing Drugs Present Key Opportunities [Yahoo! Finance]Yahoo! Finance
ABT
Earnings
- 4/17/24 - Beat
ABT
Sec Filings
- 4/17/24 - Form 8-K
- 4/2/24 - Form 4
- 4/2/24 - Form 4
- ABT's page on the SEC website